Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Wengel Kathryn E

Decker Robert J

Schmid Timothy

Wolk Joseph J

Swanson James D.

Broadhurst Vanessa

REED JOHN C

Questex's Fierce Life Sciences announced the agenda for the 16th annual PODD (Partnership Opportunities in Drug Delivery) Conference, scheduled for October 29-30, 2026, in Boston. The event will gather over 1,000 industry executives and features 150+ sessions with keynotes from Regeneron's Dr. George Yancopoulos and MIT's Dr. Robert Langer, covering topics including AI in drug delivery, pharma partnering strategies, and reimbursement challenges.

Questex’s PODD, the Premier Gathering for Drug Delivery Industry Leaders, Announces the 16th Annual Conference Agenda

The article highlights five blue-chip dividend stocks suitable for long-term buy-and-hold investing: AbbVie, McDonald's, Johnson & Johnson, Walmart, and Becton Dickinson. These companies have demonstrated decades of consecutive dividend increases and strong financial fundamentals, with dividends well-covered by earnings and solid growth prospects ahead.

5 Dividend Stocks to Buy and Hold Forever

The global hyperpigmentation treatment market is projected to grow from USD 1.52 billion in 2025 to USD 2.85 billion by 2035, expanding at a 6.5% CAGR. Growth is driven by increased consumer awareness of skin aesthetics, rising prevalence of pigmentation conditions like melasma, and adoption of advanced treatments including laser therapy and microneedling. The U.S. market is expected to reach USD 0.93 billion while Europe approaches USD 0.81 billion by 2035.

Global Hyperpigmentation Treatment Market Size to Surpass USD 2.85 Billion by 2035, Growing at a 6.5% CAGR – SNS Insider

With technology stocks comprising nearly 40% of the S&P 500's value, investors are advised to diversify into more resilient sectors like healthcare. Johnson & Johnson is highlighted as an attractive alternative due to its Dividend King status (50+ consecutive years of dividend increases), strong innovation through R&D, and the defensive nature of healthcare, which tends to be more stable during market downturns compared to volatile tech stocks.

Smart Money Is Fleeing Tech for Johnson & Johnson Ahead of the Next Market Storm

The global ovarian cancer diagnostics market is valued at USD 4.92 billion in 2025 and is projected to reach USD 8.08 billion by 2035, growing at a CAGR of 5.06%. Growth is driven by rising ovarian cancer incidence, increasing adoption of AI-powered imaging, biomarker testing, and precision oncology diagnostics. North America leads with 41.2% market share, while imaging and hospital laboratories dominate their respective segments.

Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider

Pratty ★

All stocks and economy. All the time. Except when I mix in references to sports and pop culture. Senior markets analysis writer @barronsonline. Ex-@CNNBusiness.

Paul R. La Monica

Teaching traders how to trade with conviction.

Flow Education @ BullFlow https://t.co/iWqwhYLiqb
Live Trading @ Stock Talk Insiders https://t.co/8mopfzD9l9

Danny Naz

Research-driven thematic investor & swing trader. Not financial advice

Subscribe: https://t.co/tRfuPuBAXn

Venu

USC Pharmacy Alumni, Full Time Investor. My tweets are a general reflection of my Investments and not a recommendation. Please do your own due diligence.

Johnson & Johnson (JNJ) Stock Price, Analysis & Trade Signals